Status:
COMPLETED
Methylphenidate in Myotonic Dystrophy Type 1
Lead Sponsor:
Laval University
Conditions:
Dystrophia Myotonica 1
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to determine whether methylphenidate is effective in the treatment of excessive daytime sleepiness due to myotonic dystrophy type 1 (DM1).
Detailed Description
Myotonic dystrophy type 1 (DM1) is a multisystemic disorder characterized by muscle weakness, myotonia, and the involvement of several systems. Hypersomnolence is one of the most frequently reported s...
Eligibility Criteria
Inclusion
- adults
- Epworth score ≥ 10
- Diagnosis of myotonic dystrophy type 1
Exclusion
- hypersensibility to methylphenidate
- Pregnancy
- Patients who receive drugs that interfere with methylphenidate
- Cognitive impairment
- Sleep apnea
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT01421992
Start Date
June 1 2008
End Date
September 1 2010
Last Update
August 23 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Readaptation in Physical Deficiency
Québec, Quebec, Canada, G1M2S8